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Vifllular cytidine deaminase with potent antiviral activity. In the case of HIV, the
antiviral activity of APO3G is counteracted by the viral Vif protein. Monocyte-derived macrophages (MDM)
are terminally differentiated, non-dividing cells susceptible to HIV infection. Human MDM are known to
express APO3G and HIV replication in these cells is dependent on Vif. Here we analyzed the correlation
between HIV-1 replication and APO3G expression in MDM. Replication of wild type HIV-1 induced a gradual
4–5-fold reduction in APO3G expression. The efﬁciency of APO3G downregulation correlated with the
efﬁciency of virus replication. Interestingly, despite downregulation of APO3G, the relative infectivity of
viruses rapidly declined during the course of infection and was already reduced ∼90% prior to peak virus
production. Cell-free virus preparations showed increased levels of a 41 kDa MA–CA processing intermediate.
Sequence analysis around the MA–CA cleavage site and the protease and LTR regions did not reveal
deaminase-induced hypermutation of the viral genome, suggesting that APO3G activity is not responsible for
the incomplete Gag processing. Thus, the loss of infectivity of HIV-1 viruses produced from long-term
infected primary macrophages is due to an APO3G-independent mechanism.
Published by Elsevier Inc.Introduction
The human immunodeﬁciency virus type 1 (HIV-1) accessory
protein Vif plays an important role in regulating viral infectivity
(Fisher et al., 1987; Strebel et al., 1987). Vif can counteract the antiviral
effects of the cytidine deaminase, APOBEC3G (APO3G), by inducing its
proteasomal degradation (Marin et al., 2003) or by inhibiting APO3G
encapsidation through a degradation-independent mechanism (Con-
ticello et al., 2003; Yu et al., 2003; Sheehy et al., 2003; Stopak et al.,
2003; Liu et al., 2004; Mehle et al., 2004; Kao et al., 2007; Opi et al.,
2007). In the absence of Vif, APO3G protein is efﬁciency packaged into
HIV-1 virions through a mechanism involving genomic RNA (Khan
et al., 2005; Soros et al., 2007; Khan et al., 2007), resulting in
hypermutation of the viral genome (Zhang et al., 2003; Lecossier et al.,
2003; Mangeat et al., 2003; Harris et al., 2003; Mariani et al., 2003; Yu
et al., 2004), inhibition of reverse transcription (Guo et al., 2006),
integration (Luo et al., 2007; Mbisa et al., 2007), or additionalrive MSC 0460, Bethesda, MD
rstel, Germany.
nc.deamination-independent mechanisms of virus inactivation (Shindo
et al., 2003; Newman et al., 2005; Bishop et al., 2006; Opi et al., 2006).
The intent of the current study was to investigate the relationship
between APO3G expression and HIV replication during acute virus
replication. Most T cell lines are highly sensitive to HIV-induced
cytopathicity, making it difﬁcult to study the long-term effects of Vif
on cellular APO3G. Macrophages, however, are relatively resistant to HIV
cytopathic effects and support virus replication over an extended time
period (Meltzer et al.,1990). Moreover, macrophages are refractory to the
replication of Vif-defective viruses (Kawamura et al., 1994; Gabuzda
et al., 1994; Chowdhury et al., 1996). We therefore chosemacrophages as
a model system to study HIV-1 replication over a six-week period.
Replication of HIV-1 induced a gradual 4–5-fold reduction in cellular
APO3G expression. However, HIV-1 infection never completely elimi-
nated APO3G expression even at later time points when most
macrophages in the culture were infected. Interestingly, despite the
progressive downregulation of APO3G, the relative infectivity of newly
produced virions rapidly declined during the course of infection andwas
reduced N90% after 3 weeks. Analysis of viral sequences did not reveal
any deaminase-induced mutations despite the presence of residual
APO3G. Instead, we observed an accumulation of a Gag processing
intermediate in cell-free viruses over time. Sequence analysis revealed
that the processing defect was not caused by mutations at or near the
267E. Miyagi et al. / Virology 379 (2008) 266–274processing site or in the viral protease gene, suggesting that the
reduction of viral infectivity is mediated by an APO3G-independent
mechanism that results in aberrant Gag processing.
Results
Long-term HIV-1 replication in terminally differentiated human
macrophages
Monocyte-derived macrophages (MDM) from four independent
normal donors were used to analyze the correlation between APO3G
expression and virus replication. The experimental scheme for a single
donor is outlined in Fig. 1. Brieﬂy, monocyte-derived macrophages
were plated into 24 well plates (45 wells total). Twenty-four hours
later, supernatants from all wells and cells from three wells were
collected to serve as the day 0 control. Twenty-one of the remaining
42 wells were infected with HIV-1Ada as described in Materials and
methods. The remaining 21 wells served as uninfected controls.
Uninfected and infected cultures were handled identically. Culture
supernatants (80% of total) from all wells were collected at 3-day
intervals and stored at −80 °C. Cells from three wells each of the
infected and uninfected cultures were collected at 6-day intervals for
preparation of cell lysates as outlined in Fig. 1. The progression of the
infection was monitored by comparing morphological changes in the
infected versus uninfected macrophage cultures. Cultures were
terminated 42 days post infection.
First, the efﬁciency of virus replication was determined by
quantitating HIV-1 capsid protein (CA) levels in culture supernatants
using a p24 ELISA. Supernatants from one triplicate set of infected and
uninfected cells (see Fig. 1, top) were collected and aliquots storedFig.1. Schematic representation of the experimental setup. Macrophages were plated in 24w
serum). Two plates were prepared for each donor. One plate remained uninfected to serve a
were infected with HIV-1Ada. Supernatants from all wells of the infected and uninfected plat
were pooled and used for viral protein analysis and for the analysis of APO3G-induced G–A m
were not pooled. These supernatants were used for p24 ELISA to determine the viral repli
harvested in 6 day intervals for the examination of cell-associated viral and host proteins. Tseparately for the subsequent p24 ELISA. As shown in Fig. 2,
macrophages from all four donors supported replication of HIV-1
(solid circles). Donors 1–3 exhibited similar replication proﬁles and
reached peak virus production between 24 to 30 days post infection.
Virus production from these donors was similar and reached peak p24
levels of 60 to 100 ng/ml. In contrast, macrophages derived from
donor 4 poorly supported HIV-1 replication; virus production
remained low (b20 ng/ml) over the entire 42 day observation period.
As expected, uninfected cultures did not produce detectable levels of
CA protein (open circles).
Viral protein synthesis in long-term HIV-infected macrophages
To monitor viral protein synthesis throughout the infection, cells
harvested at various times were subjected to immunoblot analysis.
Viral proteins were detectable as early as 6 days post infection (Fig. 3;
donors 1 and 2). Intracellular Pr55gag and p41gag precursor proteins
steadily increased with time and reached maximum levels at or near
peak virus production. Intracellular CA levels ﬂuctuated over the
course of infection, but these ﬂuctuations were not clearly correlated
with the production of cell-free virus (compare Figs. 2 and 3) and may
reﬂect budding of virus into intracellular compartments. Total cellular
protein levels as determined by immunoblotting (Fig. 3, tubulin) or by
protein assay (not shown) did not change noticeably over the 42 day
observation period, conﬁrming the absence of signiﬁcant HIV-induced
cytopathic effects. Of note, viral protein levels identiﬁed in donor 4-
derived cell extractswere only slightly lower relative to the other three
donors, even though donor 4 produced signiﬁcantly lower levels of
cell-free virus (see Fig. 2). HIV-1 infection induced profound changes in
the morphology of macrophages. Infection of macrophages wasell plates (0.75×106 cells/well in 1.5 ml of DMEM supplemented with 10% pooled human
s negative control. All wells of the second plate, except for the ﬁrst three wells (day 0),
e were collected in 3 day intervals. Supernatants from all wells, except the day 42 wells,
utations. Supernatants from last three cultures (day 42) were collected separately and
cation kinetics in three independent infections. Infected cells from 3 wells each were
he sampling protocol is summarized in form of a table at the bottom.
Fig. 2. HIV-1 replication in monocyte-derived macrophages (MDM). MDM (0.75×106 cells/well in 24 well plates) from four independent donors were infected with HIV-1Ada as
described in Materials and methods and in the legend to Fig. 1. Virus production was monitored for 42 days by p24 ELISA. Solid circles represent infected cultures; open circles are
uninfected control cultures. Error bars reﬂect the S.D. calculated from triplicate infections.
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abundant in infected cultures by day 24 but were absent from
uninfected controls (data not shown). Based on these morphological
changes, we estimate that the majority of macrophages in all cultures
were infected by days 18 to 24 post infection. Northern blot analysis
revealed constant levels of actin and APO3G mRNAs as well as
ribosomal RNAs in uninfected as well as infected cultures conﬁrming
that cells remained viable over the entire 42 day period (not shown).
HIV-1 infection reduces APO3G expression levels in macrophages
To examine the effects of HIV-1 infection on APO3G expression, cell
lysates from all four donors were examined by immunoblotting (Fig.
4A). Uninfected cells from donor-1 were included for reference (Fig.
4A, Control). Membranes were ﬁrst probed with an APO3G-speciﬁc
polyclonal antibody (Fig. 4A, top panels). Vif expression was then
determined by reblotting the same membrane with a Vif-speciﬁc
monoclonal antibody (middle panels). Finally, the membranes were
probed with a tubulin-speciﬁc antibody (bottom panels). APO3G
signals were quantiﬁed by densitometric scanning of the blots and
corrected for ﬂuctuations in tubulin levels. The results are shown in
Fig. 4B. APO3G levels gradually decreased with time in all infected
cultures, but remained constant in the uninfected culture demonstrat-
ing that the reduction in APO3G is a consequence of HIV-1 infection
and presumably caused by Vif. Tubulin levels were comparable in all
infected and uninfected samples, conﬁrming equal sample loading. On
average, APO3G expression was reduced 4–5 fold relative to the
uninfected control. Reduction of APO3G was somewhat less efﬁcient
in the donor 4 cells (Fig. 4B, closed triangles), which inefﬁciently
supported virus replication (see Fig. 2).
Previous reports demonstrated that HIV-1 Vif reduces APO3G
steady-state levels in transiently transfectedHeLa or 293Tcells (Stopak
et al., 2003; Marin et al., 2003; Mariani et al., 2003; Kao et al., 2003) as
well as in HIV-infectedH9 cells (Stopak et al., 2003). The effect of Vif onAPO3G is post-transcriptional and due to degradation of APO3G
(Conticello et al., 2003; Yu et al., 2003; Sheehy et al., 2003; Stopak et al.,
2003; Marin et al., 2003; Liu et al., 2004; Mehle et al., 2004).
Accordingly, we found that APO3GmRNA levels in all donors remained
constant throughout the course of infection (not shown), indicating
that the reduction of APO3G expression in HIV-infected macrophages
was largely-if not entirely-due to post-transcriptional regulation of
APO3G.Unexpectedly, however,we failed to observe a clear correlation
between Vif expression and APO3G levels. Indeed, Vif expression was
highest near peak virus production, but declined to background levels
at later times in most cultures (Fig. 4A); however, we did not observe a
concomitant reemergence of APO3G. Thus, while the initial down-
regulation of APO3G in infectedmacrophages could be attributed to Vif
expression, continued suppression of APO3G expression late in the
infection is difﬁcult to explain by Vif-induced protein degradation.
Loss of viral infectivity during long-term infection of macrophages
The reduction of APO3G in infected macrophages should prohibit
the accumulation of mutations in the viral genomes, thus ensuring
complete viral infectivity throughout the course of the infection. To
test this hypothesis, the relative infectivity of viruses collected at
various times during the infection was tested in a single-cycle assay
using TZM-bl cells as viral targets. TZM-bl cells were infected with
cell-free virus and viral infectivity was determined 48 h later by
measuring the HIV-induced luciferase activity in the target cells. The
results are shown in Fig. 5A. Supernatants collected prior to day 9
were not included in the analysis because p24 levels were too low for
normalization. Surprisingly, relative viral infectivity, i.e., the number
of infectious particles per ng p24, rapidly declined to 5 to 15% of the
infectivity of day 9 viruses within 3 weeks of culture.
To conﬁrm that this loss in viral infectivity was not a virus-speciﬁc
artifact, monocyte-derived macrophages from a normal donor were
infected with HIV-1Bal as described for HIV-1Ada in Fig. 2. Virus
Fig. 3. Intracellular viral protein expression during long-term MDM infection. Identical
portions of lysates from infectedMDMwere analyzed by immunoblotting using an HIV-
positive patient serum (top panels). Viral capsid (CA) and Gag precursors Pr55gag and
p41 are identiﬁed on the right. The same membranes were subsequently probed with a
tubulin-speciﬁc antibody to control for changes in total protein levels with time
(bottom panels).
Fig. 4. HIV infection reduces APO3G levels in MDM. (A) Cell lysates from Fig. 3 were
subjected to immunoblotting using an APO3G-speciﬁc peptide antibody (APO3G). The
same membranes were then sequentially probed with antibodies to Vif and then
tubulin. (B) APO3G-speciﬁc bands in panel Awere quantiﬁed by densitometric scanning
and expressed relative to APO3G present on day 0, which was deﬁned as 100%.
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assay (Willey et al., 1988) (Fig. 5B) and the infectivity of viruses
produced over the course of infection was determined by infection of
TZM-bl cells (Fig. 5C). Consistent with the results from Fig. 5A, the
relative infectivity of the HIV-1Bal population rapidly declined after
9 days of culture. Of note, while the relative amount of cell-free virus
was virtually the same on days 6 and 21 post infection (Fig. 5B), the
infectivity of the day 21 virus populationwas reduced by N95% relative
to the day 6 virus (Fig. 5C). Thus, the rapid loss in infectivity of viruses
produced from infected macrophages is isolate-independent.
Long-term replication in macrophages is not associated with
hypermutation of the HIV-1 genome
To determine whether the rapid loss of viral infectivity could have
been caused by hypermutation of the viral genomes due to residual
APO3G or other deaminases in the cultures, RNA fromviruses harvested
at thepeakof infection fromall 4 donorswas ampliﬁed by RT-PCR. Three
regions of the viral genome were investigated: (i) a 377 nucleotide
region from the 3′-LTR (position 9037 to 9413 of the AD8 reference
sequence); (ii) a 326 nucleotide fragment from the protease region
(position2206 to 2531); and (iii) a 437nucleotide fragment fromtheGag
region overlapping the MA–CA junction (position 979 to 1415). As a
control, RNA isolated from the input virus stock was ampliﬁed and
analyzed in parallel. Ten individual RT-PCR clones were sequenced and
compared to the input virus. The results are summarized in Table 1. We
were unable to ﬁnd any evidence of APO3G-induced hypermutation inthe more than 34,000 nucleotides sequenced. The overall frequency of
G–Amutationwas low and not signiﬁcantly different from that of other
random mutations. These results suggest that the gradual loss of viral
infectivity during HIV-1 replication in macrophages was not caused by
an accumulation of APOBEC-induced mutation of the viral genomes.
To further conﬁrm that the loss in viral infectivity during long-term
infection of macrophages was transient, we used virus-containing
supernatants harvested from donor 1 on days 9 and 21 (see Fig. 2) and
compared their relative replication ﬁtness in a second round of
infection. For that purpose, equal infectious units of day 9 and day 21
virus, as determined in Fig. 5A, were used to infect monocyte-derived
macrophages from a normal donor. Virus replication was monitored
by reverse transcriptase assay (Fig. 5D). We found that virus harvested
on day 21 of the initial infection replicated as efﬁciently, if not better,
than the day 9 virus suggesting that it had not suffered a permanent
Fig. 5. Relative viral infectivity declines during long-term replication in MDM. (A) Virus-
containing supernatants collected at various times in Fig. 2 were used to infect TMZ-bl
indicator cells. Infection was determined 48 h later by measuring the Tat-induced
luciferase activity in the target cells. Results were normalized for equal amounts of p24
by ELISA and expressed relative to the infectivity of day 9 virus, which was deﬁned as
100%. (B)Monocyte-derivedmacrophages from a normal donor were infectedwith HIV-
1Bal as described in Materials and methods and in the legend to Fig. 1. Virus production
wasmonitored for 30 days bymeasuring the reverse transcriptase activity in the culture
supernatants. Infections were done in triplicates. (C) The relative infectivity of virus
produced in panel B was determined by single-cycle infection of TMZ-bl indicator cells.
Infection was determined 24 h later as in panel A. Results were normalized for equal
amounts of input reverse transcriptase activity. (D) Monocyte-derived macrophages
from a normal donor were infected in triplicate with virus collected on days 9 and 21,
respectively, from donor 1-infected cultures (Fig. 2). Virus input was normalized for
equal infectious doses as determined in panel A (donor 1). Virus replication was
monitored as in panel B. Error bars in panels A–D reﬂect S.D. from triplicate infections.
Table 1
G–A and non G–A mutations accumulating in viral RNA
(%) 3′ LTR Protease MA–CA
G–A Other G–A Other G–A Other
Donor 1 0.14 0.58 0.03 0.41 0 0.06
Donor 2 0.06 0.12 0.06 0.35 0.03 0
Donor 3 0.04 0.30 0.09 0.32 nt nt
Donor 4 0.13 0.35 0.07 0.42 nt nt
nt=not tested.
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sequencing data (Table 1) suggesting that loss of viral infectivity
during long-term propagation in macrophages was not caused by the
accumulation of mutations in the viral genomes but, instead was due
to transient host-speciﬁc effects.
Virions from long-term HIV-infected macrophages reveal aberrant Gag
processing
To determine potential reasons for the loss of viral infectivity
during the course of virus replication in MDM, we compared the
protein proﬁles of virions harvested at various times during the
infection. Viral supernatants were normalized by ELISA for equal p24
levels and concentrated by pelleting through 20% sucrose. Pelleted
viruses were subjected to immunoblotting using an HIV-positive
patient serum. As expected, the levels of p24 (CA) were constant in all
samples at all time points (Fig. 6A, CA). Levels of virus-associated Env
proteinwere too low to be detected by immunoblotting. Interestingly,
we noted increasing amounts of a 41 kDa Gag product in the virus
preparations from all four donors (Fig. 6A, p41). Re-analysis of day 24
samples from donors 1 and 2 with antibodies to matrix (Fig. 6B, α-
MA), capsid (Fig. 6B, α-CA), or nucleocapsid (Fig. 6B, α-NC) revealed
cross-reactivity of the p41 band with both the MA- and CA-speciﬁc
antibodies, but not the NC antibody (Fig. 6B, p41). These results
suggest that long-term replication of HIV-1 in macrophages results in
the gradual accumulation of a MA–CA processing intermediate.
Sequence analysis of the region around the MA–CA cleavage site did
not reveal an accumulation of mutations that could explain the altered
processing proﬁle (Table 1).
To address the possibility that loss of viral infectivity was due to a
gradual loss in virus-associated envelope protein, we metabolically
labeled virus from infected macrophages on days 9 and 30 post infection
(Fig. 6C). Uninfected macrophages were labeled as a control (Fig. 6C,
uninf). Labeled viral supernatants were collected 24 h later and
immunoprecipitated with an HIV-1 positive human patient serum. As
can be seen in Fig. 6C, similar amounts of virus-associated CA protein
were present in the immunoprecipitates from day 9 and day 30
supernatants. Importantly, the amounts of virus-associated envelope
protein were also very similar for the day 9 and day 30 viruses (Fig. 6C,
Env), suggesting that the rapid loss of infectivity of the macrophage-
derivedviruseswasdue toanenvelope-independentphenomenon.Aside
fromthedisappearanceof a∼33kDaHIVproduct and the appearanceof a
∼60 kDa protein in the day 30 sample, the accumulation of the 41 kDa
MA–CA Gag processing intermediate is the only obvious anomaly in
viruses produced late during HIV replication in human macrophages.
Loss of viral infectivity is not caused by a putative soluble inhibitory
factor in macrophage-derived viral supernatants
It is well-documented that HIV-1 infection and virus replication in
human macrophages can be modulated by numerous cytokines,
chemokines, and growth factors. Many of these can be produced by
the macrophages themselves and can function in a stimulatory or
inhibitory manner. Among the endogenously produced factors shown
to inhibit HIV-1 replication in macrophages is interferon-β, beta-
Fig. 6. Long-term replication results in the accumulation of a virus-associated 41 kDa CA–MA precursor. (A) Culture supernatants from days 9 to 36 were ﬁltered through 0.45 μm
syringe ﬁlters to remove cellular debris. Virus particles corresponding to 25 ng of p24 as determined by ELISAwere then puriﬁed by pelleting through 20% sucrose. Viral pellets were
solubilized in loading buffer, separated by SDS-12.5% PAGE, subjected to immunoblotting using an HIV-positive patient serum. Viral capsid (CA) and p41 precursor proteins are
identiﬁed on the right. (B) Viral samples from donors 1 and 2 collected 24 days post infection were puriﬁed as in panel A and subjected to immunoblotting using an HIV-positive
patient serum (APS) or antibodies to matrix (α-MA), capsid (α-CA), or nucleocapsid (α-NC) proteins. Viral proteins are identiﬁed on the right. (C) HIV-infected macrophages were
metabolically labeled with [35S]-methionine on days 9 and 30 post infection and immunoprecipitated with an HIV-1 positive patient serum as described in Materials and methods.
Viral proteins are identiﬁed on the right.
271E. Miyagi et al. / Virology 379 (2008) 266–274chemokines Mip-1α, Mip-1β, and Rantes (Gessani et al., 1994; Pal
et al., 1997; Struyf et al., 1998;Moriuchi andMoriuchi,1999; Cota et al.,
2000; Agrawal et al., 2002; Peng et al., 2006). It is therefore
conceivable that the low infectivity of late-term virus is not due to a
defect in the virus, but is caused by the presence of host-derived
inhibitory factors secreted into the virus-containing supernatants. To
investigate whether the rapid decline in the relative infectivity of HIV-
1 produced from infected macrophage cultures is caused by soluble
inhibitory factors present in the culture supernatants, we analyzed
virus-containing supernatants harvested on days 9, 21, and 30 post
infection and compared their relative infectivities. Supernatants were
either left untreated and used directly for infection of target cells
(Fig. 7, untreated virus) or virions were pelleted to remove the
conditioned culture supernatant and then resuspended in an equal
volume of fresh unconditioned culture medium (Fig. 7, pelleted virus)
prior to infection. Consistent with the results from Fig. 5 we found that
the infectivity of untreated viruses collected on days 21 and 30 was
∼5–6 times lower than that of day 9 virus (Fig. 7, untreated virus).
Importantly, the infectivity of these viruses remained low even afterreplacement of the culture medium. These results suggest that virus-
containing supernatants from HIV-infected macrophages do not
contain macrophage-derived soluble factors capable of interfering
with viral infectivity in a single-cycle assay.
Discussion
Unlike the lytic infection of CD4+T cells, HIV-infected macro-
phages show little or no virus-induced cytopathic effects (Meltzer et
al., 1990). This enabled us to study long-term relationships between
Vif, APO3G, and viral infectivity. Importantly, Vif is essential for
replication of HIV in primary macrophages (Kawamura et al., 1994;
Gabuzda et al., 1994; Chowdhury et al., 1996) presumably to
counteract the antiviral activity of APO3G (Peng et al., 2006).
Previous studies have shown that Vif-dependent reduction of
APO3G is due to a post-transcriptional effect of Vif on APO3G
(Mariani et al., 2003; Kao et al., 2003; Stopak et al., 2003; Marin
et al., 2003). We hypothesized that Vif-induced degradation of
APO3G should positively inﬂuence virus infectivity by preventing
Fig. 7. Loss of viral infectivity is not caused by a putative inhibitory factor in
macrophage-derived viral supernatants. MDM were infected with HIV-1Ada as
described in Materials and methods. Viral supernatants (500 μl ea.) from days 9
(early), 21 (peak) and 30 (late) were ﬁltered and pelleted in a refrigerated Eppendorf
microcentrifuge (4 °C) for 90 min at 16,000 ×g as reported previously (Schubert et al.,
1995). For “untreated virus”, the viral pellets were resuspended in its original
supernatant. For “pelleted virus”, the culture supernatants were removed and the
pelleted viruses were suspended in 500 μl of fresh medium. Viruses were then
normalized for equal RT activity and used for the infection of TZM-bl indicator cells.
Infection was determined 48 h later by measuring the Tat-induced luciferase activity in
the target cells. Results were expressed relative to the infectivity of untreated day 9
virus, which was deﬁned as 100%. Error bars reﬂect S.D. from triplicate infections.
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found that APO3G expression was reduced in HIV-infected macro-
phages. Unexpectedly, reduction in APO3G expression did not
directly correlate with Vif expression (Fig. 4A). Instead, following a
gradual decline during the ﬁrst 2 weeks of infection, APO3G levels
remained repressed throughout the remainder of the study despite
a signiﬁcant decline in Vif expression subsequent to peak virus
production. This suggests that in addition to Vif-dependent down-
regulation of APO3G by protein degradation, repression of APO3G in
infected macrophages at later stages of infection may involve
additional presumably Vif-independent mechanisms.
The reason for the rapid loss of viral infectivity during virus
replication in macrophages is not entirely clear. We noticed a gradual
accumulation over time of a 41 kDa Gag processing intermediate in
cell-free viruses from all donors (Fig. 6, arrows). While differential
immunoblotting identiﬁed this protein as a MA–CA processing
intermediate, the reason for its accumulation during the course of
the infection remains obscure. Mutation frequencies in viruses
derived from donor 4 cultures in which APO3G downregulation was
less efﬁcient than in the other cultures (Fig. 4) were not higher than
those derived from other donors (Table 1) arguing against a control of
viral ﬁtness through deaminase-induced hypermutation of the viral
genomes. Also, we were unable to identify any mutations at or near
the MA–CA cleavage site or within the protease region that could
explain the reduced processing at the MA–CA cleavage site (Table 1).
Recently, deaminase-independent antiviral effects of APO3G have
been reported aswell (Newman et al., 2005; Guo et al., 2006; Opi et al.,
2006; Bishop et al., 2006;Mbisa et al., 2007; Luo et al., 2007; Guo et al.,
2007). However, these effects required virus-encapsidation of APO3G
and were most prominent at high levels of APO3G expression (Miyagi
et al., 2007; Schumacher et al., 2008). In our experiments, we were
unable to identify APO3G in cell-free virions (not shown). This was
expected because of the presence of Vif. It seems therefore unlikely
that the rapid loss of viral infectivity could have been caused by
deaminase-independent effects of APO3G. Furthermore, we tested the
packaging of Env protein into cell-free viruses at early and late stages
of infection and did not notice any packaging defects that could
explain the loss of infectivity (Fig. 6C). Finally, we ruled out that
potential macrophage-derived inhibitory factors conceivably present
in virus-containing culture supernatants could account for the
observed loss of viral infectivity.Thus, the most likely cause of the loss in infectivity is the noted
accumulation of a 41 kDa MA–CA processing intermediate. It is
important to note that only a small fraction of the virus-associated Gag
molecules was incompletely processed, while the majority of the Gag
precursors were processed into mature CA protein at all times (Fig.
6A). This observation is consistent with the absence of processing site
mutations or mutations in the viral protease gene, since such
mutations would be expected to cause a general processing defect.
The observed partial inhibition of Gag processing could be explained
by the packaging of host or viral factors late in infection. Such factors
could bind to the Gag precursor at or near the MA–CA processing site
and thus inhibit cleavage by steric hindrance. In this regard, we have
previously found that packaging of increasing amounts of Vif protein
into viral particles resulted in an assembly defect caused by steric
interference of Vif with processing of Gag at its primary cleavage site.
The resulting accumulation of a 34 kDa CA–NC intermediate severely
affected the infectivity of cell-free virions (Akari et al., 2004). It is
therefore possible that the accumulation of the p41 MA–CA
intermediate in late-stage virus preparations similarly reﬂects the
packaging of an as yet unidentiﬁed cellular Gag-interacting factor
that – by means of interference with Gag processing – causes an
assembly defect and a concomitant loss of viral infectivity through a
dominant-negative mechanism.
Materials and methods
Preparation of monocyte-derived macrophages and infection
Humanmonocytes frommultiple normal donorswere elutriated as
described (Gruber et al., 1995). Monocytes were cultured in complete
DMEM supplementedwith 10% pooled human serum for 6 to 7 days to
allow differentiation into macrophages (MDM). Macrophages were
harvested and re-plated into 24-well plates at 0.75×106 cells/well in
l.5 ml. For infection, 1.2 ml of culture supernatant was removed and
30 μl of 10×HIV-1Ada or HIV-1Bal virus stocks (Advanced Biotechnol-
ogies Inc, Columbia, MD) were added. Virus was allowed to adsorb for
4 h at 37 °C before 1.2ml of completeDMEMwere added back.Medium
(1.2ml) was replaced and culture supernatants were collected at 3 day
intervals. Virus-containing supernatants were clariﬁed by centrifuga-
tion, ﬁltered through a 0.45 μm ﬁlter and stored at −80 °C for further
analysis. Virus concentration in culture supernatants was determined
by HIV-1 p24 antigen ELISA (ZeptoMetrix Corp, Buffalo, NY).
Immunoblotting
For immunoblot analysis of viral supernatants, equal amounts of
virus as determined by p24 ELISA were pelleted through 4 ml of 20%
sucrose (75 min, 35,000 rpm, SW41). Virus pellets were solubilized in
sample buffer (2% SDS, 62.5 mM Tris–HCl pH 6.8, 5% 2-mercaptoetha-
nol, 5% glycerol, 0.001% bromophenol blue) and heated at 95 °C for
10min. For western blot analysis of cell-associated proteins, cells were
washed twicewith PBS and lysed in 200 μl of Chaps buffer (50mMTris
pH 8.0, 5 mM EDTA, 150 mM NaCl, 0.5% w/v CHAPS, 0.2%
deoxycholate). Insoluble material was pelleted and supernatants
were ﬁltered through 0.45 μm Spin-X ﬁlters (Corning Inc., Acton,
MA). Protein concentrationswere determined using a Protein assay kit
(BioRad Laboratories, Hercules, CA). Samples were mixed with an
equal volume of sample buffer and heated at 95 °C for 10 min. Cell
lysates (25 μg/lane) or concentrated viral extracts (normalized by p24
ELISA) were separated by SDS-12.5% polyacrylamide gel electrophor-
esis (SDS-PAGE). Proteins were transferred to PVDF membranes
(Millipore Corp., Bedford, MA) and reacted with appropriate anti-
bodies. HIV-1-speciﬁc capsid and Gag precursor proteins were
detected using an HIV-seropositive patient serum (APS). APO3G was
identiﬁed using a polyclonal peptide serum (Apo-C17). Matrix protein
was identiﬁed with a mouse-monoclonal antibody (Fitzgerald
273E. Miyagi et al. / Virology 379 (2008) 266–274Industries International, Concord, MA). A capsid-speciﬁc monoclonal
antibody (mAB #24–3) was a gift of Michael Malim and was obtained
through the NIH AIDS Research and Reference Reagent Program (Cat-
No: 6458). A goat polyclonal antibody to nucleocapsid (NC) was a gift
of Robert Gorelick. Tubulin was identiﬁed using a monoclonal
antibody to α-tubulin (Sigma-Aldrich, St. Louis, MO). Membrane-
bound antibodies were identiﬁed using horseradish peroxidase-
conjugated secondary antibodies (Amersham Biosciences, Piscataway,
NJ) and visualized by enhanced chemiluminescence (ECL) (Amersham
Biosciences).
Infectivity assay
Viral infectivity was determined in a single-cycle assay by
measuring the virus-induced luciferase activity in infected TZM-bl
cells, obtained from John Kappes through the NIH AIDS Research and
Reference Reagent Program (Wei et al., 2002). Cells were maintained
in complete DMEM supplemented with 10% FBS. For infection, TZM-
bl cells (5×104) were plated into 24 well plates and allowed to
adhere for 24 h. Virus-containing supernatants were then added and
cells were incubated for 24 to 48 h at 37 °C. Cells were washed twice
with 1 ml of cold PBS, and lysed in 300 μl of Passive Lysis Buffer
(Promega Corp., Madison, WI). To determine the luciferase activity,
20 μl of each lysate were combined with luciferase substrate
(Promega) by automatic injection and light emission was measured
for 10 s at room temperature in a luminometer (Optocomp II; MGM
Instruments, Hamden, CT).
RT-PCR
Virus-containing supernatants from day 24 (donor 1 and 2) and
day 30 (donor 3 and 4) were concentrated using VIVASPIN
concentrators with a 100,000 MW cut-off (Sartorius Corp., Edge-
wood, NY). Input HIV-1Ada was analyzed in parallel. Viral RNA was
extracted using a QIAamp viral RNA mini kit (QIAGEN, Valencia, CA)
following the manufacturer's instructions and treated with DNase I
(10 U, 37°C, 30 min) to eliminate contaminating DNA. DNase was
heat-inactivated (75 °C, 10 min) and sequences of the 3′ LTR region
were ampliﬁed by RT-PCR using the Super Script III™ One Step RT-
PCR System (Invitrogen Corp., Carlsbad, CA) and primers AD8-LTR-5′
(CAGTAGATCT TAGCCACTTT TTAA) and AD8-LTR-3′ (TCGATGTCAG
CAGTCTTTGT AGTA). Sequences of the protease region were
ampliﬁed by RT-PCR using primers AD8-PR-5′ (TCTCAGAAGC
AGGAGCCGAT AGAC) and AD8-PR-3′ (AAGCTGAGTC AACAGATTTC
TTCC). Sequences around the MA–CA junction were ampliﬁed using
primers AD8-p17/p24-5′ (CTACAACCAT CCCTTCAGAC) and AD8-p17/
p24-3′ (GCTTCCTCAT TGATGGTCTC). RT-PCR products were cloned
into the TA cloning vector pGEM-T (Promega Corp., Madison, WI).
Ten individual clones from each set were sequenced, totaling 3160
to 4600 nucleotides per set.
Metabolic labeling and immunoprecipitation
Monocytes were distributed into 6 well plates in 2 ml of DMEM
(4×106 cells/well). Cells were allowed to adhere for 2 h at 37 °C, then
the medium was replaced with complete DMEM supplemented with
10% pooled human serum (2 ml per well) and incubation was
continued for 6 days to allow differentiation into macrophages.
Mediumwas removed from all wells and ﬁvewells were infected with
600 μl each of 1×HIVAda; one well remained uninfected and received
600 μl of DMEM. Virus was allowed to adsorb for 4 h at 37 °C before
1.4 ml of complete DMEM was added. Medium (1.5 ml ea.) was
replaced and culture supernatants were collected at 3 day intervals
and RT assays were performed to check viral replication kinetics.
Metabolic labeling of virus was performed on day 9 using 3 of the
infected wells or on day 30 using 2 wells. The uninfected cells werealso labeled on day 30. Cells were labeled with [35S]-methionine
(400 μCi/ml) for 4 h, then another 400 μCi of isotope were added and
labeling was continued overnight. Labeled supernatants were clariﬁed
by centrifugation and ﬁltered (0.45 μm spin tube; Spin-X, Costar).
Filtered virions were then pelleted through 20% sucrose (SW41,
35,000 rpm; 75 min) to remove soluble viral proteins. Viral pellets
were lysed in NP-40/DOC lysis buffer and immunoprecipitated using a
HIV-1 positive human patient serum.
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